Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Comparing Antipsychotic Medications in LBD Over Time
- Conditions
- Dementia With Lewy BodiesParkinson's Disease Psychosis
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 94
- Registration Number
- NCT05590637
- Locations
- 🇺🇸
University Health System, San Antonio, Texas, United States
🇺🇸UT Health Science Center - San Antonio, San Antonio, Texas, United States
Chinese Longitudinal and Systematic Study of Bioplar Disorder
- Conditions
- Bipolar Disorder, MixedMajor Depressive DisorderAffective; Disorder, Organic
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 10000
- Registration Number
- NCT05480150
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Trazodone vs. Quetiapine for the Treatment of ICU Delirium
- Conditions
- Delirium, Sepsis AssociatedPsychDeliriumDelirium of Mixed OriginDelirium in Old AgeMoralityDelirium Confusional StateTreatment Side Effects
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 60
- Registration Number
- NCT05307003
- Locations
- 🇺🇸
Keck Hospital of the University of Southern California, Los Angeles, California, United States
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Flinders University
- Target Recruit Count
- 15
- Registration Number
- NCT05303935
- Locations
- 🇦🇺
Adelaide Institute for Sleep Health, Adelaide, South Australia, Australia
Sleep Disorders in Chronic Kidney Disease Patients
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT05240261
Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Federal Stare Budgetary Scientific Institution, Mental Health Research Center
- Target Recruit Count
- 30
- Registration Number
- NCT05098353
- Locations
- 🇷🇺
Mental health research center, Moscow, Russian Federation
RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)
- Conditions
- MoralityQuality of LifeDeliriumPsychTreatment Side Effects
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 30
- Registration Number
- NCT05085808
- Locations
- 🇺🇸
Keck Hospital of the University of Southern California, Los Angeles, California, United States
The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Verinder Sharma
- Target Recruit Count
- 22
- Registration Number
- NCT04950868
- Locations
- 🇨🇦
Parkwood Institute, London, Ontario, Canada
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 150
- Registration Number
- NCT04936126
- Locations
- 🇮🇳
All India Institute of Medical Sciences, Bhubaneswar, Orissa, India
Improving Sleep After TKA Using Mirtazapine and Quetiapine
- Conditions
- Osteo Arthritis KneeInsomnia
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- St. Anna Ziekenhuis, Geldrop, Netherlands
- Target Recruit Count
- 165
- Registration Number
- NCT04728581
- Locations
- 🇳🇱
St. Anna hospital, Geldrop, Netherlands
🇳🇱Knowledge Center for Orthopedic Surgery, St. Anna hospital, Geldrop, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.